You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK):國家藥監局受理百澤安新適應症上市申請
阿思達克 04-22 18:11
百濟神州(06160.HK)公布,國家藥監局受理旗下抗PD-1抗體藥物「百澤安」聯合兩項化療方案的新適應症上市申請。

該產品將用於治療一線晚期鱗狀非小細胞肺癌(NSCLC),百濟神州中國區總經理兼公司總裁吳曉濱表示,百澤安於近期在中國獲批用於治療尿路上皮癌,由啟動該項臨床試驗到遞交上市申請僅花20個月,期待就該項申請與藥品審評中心展開密切合作,為晚期鱗狀NSCLC患者提供全新治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account